Bypassing phase 1 trials in the cancer drug development paradigm: Generally unwise and potentially dangerous
نویسندگان
چکیده
منابع مشابه
Cancer immunotherapy trials: leading a paradigm shift in drug development
Background Cancer immunotherapy has a long history in the clinic. William Coley was an orthopedic surgeon in the late 1800’s who noted marked tumor regression in a patient with severe erysipelas. Based on this observation, he hypothesized that stimulating the immune system could effectively treat cancer. Thus, over the next decades he gave various bacterial products, including live bacteria, to...
متن کاملthe survey of the virtual higher education in iran and the ways of its development and improvement
این پژوهش با هدف "بررسی وضعیت موجود آموزش عالی مجازی در ایران و راههای توسعه و ارتقای آن " و با روش توصیفی-تحلیلی و پیمایشی صورت پذیرفته است. بررسی اسنادو مدارک موجود در زمینه آموزش مجازی نشان داد تعداد دانشجویان و مقاطع تحصیلی و رشته محل های دوره های الکترونیکی چندان مطلوب نبوده و از نظر کیفی نیز وضعیت شاخص خدمات آموزشی اساتید و وضعیت شبکه اینترنت در محیط آموزش مجازی نامطلوب است.
Phase 1 trials in pancreatic cancer.
Despite many clinical trials over the last two decades since the approval of gemcitabine, the survival of patients with pancreatic cancer has improved by a few only months. This disappointing reality underlines an urgent need to develop more effective drugs or better combinations. A variety of phase I trials were presented at the annual meeting of ASCO 2014 focusing on locally advanced and meta...
متن کاملthe importance of clinical trials in drug development
while preclinical research answers basic questions about a drug’s safety, it is not a substitute for studies of ways the drug will interact with the human body. “clinical research” refers to studies, or trials, that are done in people 1,2. as the developers design the clinical study, they will consider what they want to accomplish for each of the different clinical research phases and begin the...
متن کاملNew Results Will Change the Paradigm for Phase I Trials and Drug Approval
Disclosures: Bruce A. Chabner: Employment/leadership position: Massachusetts General Hospital, Harvard; Consultant/advisory role: Sanofi, Redwood, Allergan, Epizyme, PharmaMar, GSK (Pending); Honoraria: Eli Lilly; Research funding/contracted research: U.S. Government; Ownership interest: PharmaMar, Gilead, Merck, Epizyme, Human Genome Sciences, Curis, Onyx, Rigel, Bristol-Myers. The content of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2010
ISSN: 0008-543X
DOI: 10.1002/cncr.25543